{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:10:22Z","timestamp":1790262622187,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"DOI":"10.1007\/s40291-026-00881-2","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:56:58Z","timestamp":1790261818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gadoquatrane: First Approval"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"8","key":"881_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/RLI.0000000000001259","volume":"61","author":"J Endrikat","year":"2025","unstructured":"Endrikat J, Siddiqui I, Khater H, et al. Rationales for non-standard GBCA dosing\u2014Low?\u2014High?\u2014When? and Why? A literature-based study. Invest Radiol. 2025;61(8):575\u201386.","journal-title":"Invest Radiol"},{"issue":"3","key":"881_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.33590\/emj\/ZRVN2069","volume":"9","author":"MT Islam","year":"2024","unstructured":"Islam MT, Tsnobiladze V. The application, safety, and recent developments of commonly used gadolinium-based contrast agents in MRI: a scoping review. EMJ. 2024;9(3):63\u201373.","journal-title":"EMJ."},{"key":"881_CR3","unstructured":"Bayer HealthCare Pharmaceuticals Inc. AMBELVIST\u00ae (gadoquatrane) injection, for intravenous use: US prescribing information. 2026. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/ambelvist_PI.pdf. Accessed 30 July 2026."},{"key":"881_CR4","unstructured":"Bayer Pharma Navi. AMBELVIST\u00ae (gadoquatrane) injection, for intravenous use: Japanese prescribing information. 2026. https:\/\/pharma-navi.bayer.jp\/sites\/g\/files\/rptbxg576\/files\/2026-05\/AMB_S_MPI_20260521.pdf. Accessed 30 July 2026."},{"issue":"10","key":"881_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/RLI.0000000000000889","volume":"57","author":"J Lohrke","year":"2022","unstructured":"Lohrke J, Berger M, Frenzel T, et al. Preclinical profile of gadoquatrane: a novel tetrameric, macrocyclic high relaxivity gadolinium-based contrast agent. Invest Radiol. 2022;57(10):629\u201338.","journal-title":"Invest Radiol"},{"issue":"11","key":"881_CR6","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/RLI.0000000000001195","volume":"60","author":"S Gruendemann","year":"2025","unstructured":"Gruendemann S, Frenzel T, Lohrke J, et al. In vitro and in vivo stability assessment of the novel, macrocyclic gadolinium-based contrast agent gadoquatrane. Invest Radiol. 2025;60(11):768\u201378.","journal-title":"Invest Radiol"},{"key":"881_CR7","unstructured":"Bayer. First approval for Bayer\u2019s low-dose MRI contrast agent in Japan. Media release. 23 Mar 2026;http:\/\/www.bayer.com."},{"key":"881_CR8","unstructured":"Bayer. Bayer\u2019s low-dose MRI contrast agent approved in U.S. Media release. 15 Jun 2026. http:\/\/www.bayer.com."},{"key":"881_CR9","unstructured":"Bayer. AMBELVIST\u00ae (gadoquatrane) injection for intravenous use: Canadian product monograph. 2026. https:\/\/pdf.hres.ca\/dpd_pm\/00085559.PDF. Accessed 12 Aug 2026."},{"key":"881_CR10","unstructured":"Bayer. Bayer files for EU approval of gadoquatrane. Media release. 10 Jul 2025. http:\/\/www.bayer.com."},{"key":"881_CR11","unstructured":"Bayer. New drug application for gadoquatrane accepted for review in China. Media release. 18 Sep 2025. http:\/\/www.bayer.com."},{"issue":"12","key":"881_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/RLI.0000000000001098","volume":"59","author":"BM Hofmann","year":"2024","unstructured":"Hofmann BM, Riecke K, Klein S, et al. Relationship of dose and signal enhancement properties of gadoquatrane, a new tetrameric, macrocyclic gadolinium-based contrast agent, compared with gadobutrol: a randomized crossover study in healthy adults. Invest Radiol. 2024;59(12):845\u201353.","journal-title":"Invest Radiol"},{"key":"881_CR13","unstructured":"G. Jost, J. Boyken, J. Lohrke, et al. One-year follow-up of gadolinium presence and distribution in rat bones: evaluation of the novel, high-relaxivity contrast agent gadoquatrane compared to gadopiclenol and gadobutrol [abstract]. In: European Congress of Radiology. 2026."},{"key":"881_CR14","doi-asserted-by":"crossref","unstructured":"Mentzel H, Sutter G, von M\u00fcnchhausen C, et al. QUANTI Pediatric-studie: pharmakokinetik und sicherheit des niedrigdosierten gadoquatrane in der kontrastverst\u00e4rkten MRT bei kindern und jugendlichen [abstract no. ab146]. R\u00f6Fo-Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren. 2026;198(S 01):S52.","DOI":"10.1055\/s-0046-1817570"},{"key":"881_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2024.106749","volume":"196","author":"X He","year":"2024","unstructured":"He X, Matsuki S, Li K, et al. Pharmacokinetics, safety, and tolerability of the novel tetrameric gadolinium-based MRI contrast agent gadoquatrane in healthy Chinese and Japanese men: two randomized dose-escalation studies including concentration\u2013QTc modeling. Eur J Pharm Sci. 2024;196:1\u201310.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"881_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/RLI.0000000000001043","volume":"59","author":"BM Hofmann","year":"2024","unstructured":"Hofmann BM, Riecke K, Klein S, et al. Pharmacokinetics, safety, and tolerability of the novel tetrameric, high-relaxivity, macrocyclic gadolinium-based contrast agent gadoquatrane in healthy adults. Invest Radiol. 2024;59(2):140\u20139.","journal-title":"Invest Radiol"},{"issue":"11","key":"881_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/RLI.0000000000001191","volume":"60","author":"T Fadini","year":"2025","unstructured":"Fadini T, Sutter G, Klein S, et al. Pharmacokinetics, safety, and dialyzability of gadoquatrane in patients with impaired renal function: a comprehensive investigation using clinical trial data, modeling and simulation, and in vitro data. Invest Radiol. 2025;60(11):779\u201390.","journal-title":"Invest Radiol"},{"key":"881_CR18","doi-asserted-by":"crossref","unstructured":"Deuschl C, Hodge S, Liu A, et al. Ergebnisse der QUANTI CNS-studie: wirksamkeit und sicherheit von gadoquatrane bei patienten mit kontrastverst\u00e4rkter MRT des ZNS mit reduzierter gadolinium-dosis im vergleich zu makrozyklischen GBCAs [abstract no. 102]. R\u00f6Fo-Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren. 2026;198(S 01):S36\u20137.","DOI":"10.1055\/s-0046-1817526"},{"key":"881_CR19","doi-asserted-by":"crossref","unstructured":"Luetkens J, Fursenko V, Liu A, et al. Die QUANTI OBR-studie: wirksamkeit und sicherheit von gadoquatrane bei patienten mit kontrastverst\u00e4rkter MRT des k\u00f6rpers mit reduzierter gadolinium-dosis im vergleich zu makrozyklischen GBCAs [abstract]. R\u00f6Fo-Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren. 2026;198(S 01):S36.","DOI":"10.1055\/s-0046-1817524"},{"issue":"Supplement 1","key":"881_CR20","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.jocmr.2025.102614","volume":"28","author":"JA Luetkens","year":"2026","unstructured":"Luetkens JA, Fursenko V, Liu A, et al. Subanalysis of cardiac MRI of a phase 3 trial investigating safety and efficacy of gadoquatrane for low-dose contrast-enhanced MRI of the body [abstract no. 2210612]. J Cardiovasc Magn Reson. 2026;28(Supplement 1):102614.","journal-title":"J Cardiovasc Magn Reson"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00881-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00881-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00881-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:57:08Z","timestamp":1790261828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00881-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":20,"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00881-2","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"2 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Fung is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}